HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam is supported by a differentiated, patented platform that captures cardiac electrical activity in three dimensions and synthesizes a 12-lead ECG, giving it a credible clinical advantage in arrhythmia, ischemia, and heart attack assessment outside traditional care settings. Its fundamentals are strengthened by FDA clearance, early commercial traction through ClearCardio and Atelier Health, and expanding addressable markets, including an approximately $2B MCT segment and a direct-pay opportunity of roughly 1.5 million patients with an initial ARR potential of $75M-$150M at 10% penetration. Although 1Q26 showed no revenue and a $4.7M net loss, disciplined cost control, a recent $11.5M equity offering, and expected meaningful revenue in 2H26 provide runway while pilot studies and strategic partnerships reduce commercialization risk.

HeartBeam is facing a fundamentally weak investment case because it is abandoning a large commercial push for arrhythmia and instead shifting scarce resources toward an MI indication that still requires clinical validation, algorithm development, and a regulatory path before any meaningful revenue can emerge. The company has no visibility into the timing of MI approval or market entry, and despite encouraging pilot study enrollment, its near-term model implies limited revenue while 2Q26 posted a $5.0M net loss, a $3.3M operating cash outflow, and just $8.7M in cash at the end of June 2026. That liquidity profile, combined with the expectation of another capital raise within 12 months and explicit risks around dilution, trial failure, competition, and going concern, supports a negative outlook.